These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22292360)

  • 1. [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs].
    Xie Y; Wei X
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2768-70. PubMed ID: 22292360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Discussion on development of four diagnostic information scale for clinical re-evaluation of postmarketing herbs].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3548-50. PubMed ID: 22368876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
    Tian F; Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Apr; 36(8):1097-102. PubMed ID: 21809593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].
    Xie Y; Wang Y; Tian F; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real-world study: a potential new approach to effectiveness evaluation of traditional Chinese medicine interventions].
    Tian F; Xie YM
    Zhong Xi Yi Jie He Xue Bao; 2010 Apr; 8(4):301-6. PubMed ID: 20388468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
    Xiao Y; Zhao Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
    Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thought on several problems of post-marketing herbs clinical evaluation in special populations].
    Zhou A; Lian F
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2776-8. PubMed ID: 22292362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
    Wang X; Su X; Yu J; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Skin test: guide of post-marketed re-evaluation of clinical safety in traditional Chinese medicine injection].
    Wei X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2877-9. PubMed ID: 22292390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies with traditional Chinese medicine in the past decade and future research and development.
    Jiang M; Yang J; Zhang C; Liu B; Chan K; Cao H; Lu A
    Planta Med; 2010 Dec; 76(17):2048-64. PubMed ID: 20979016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)].
    Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].
    Wei X; Ye X; Xie Y; Zou Y; Zhao X; Han J; Wang X; Ma Y; Bi Q; Xie Q; Zhao J; Cao X; Chen H; Wang S; Yan R; Han Z; Yi D; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2789-92. PubMed ID: 22292366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influencing factor and mechanism analysis of adverse drug reaction in traditional Chinese medicine injection].
    Wei X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2748-51. PubMed ID: 23285926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.